Navigation Links
Alexza Announces Submission of AZ-004 (Staccato(R) Loxapine) NDA
Date:12/14/2009

appears more noticeable to others as they become threatening and potentially violent, especially if the agitation is not treated. While patients seek treatment at different points along this agitation continuum, those with the most severe symptoms generally require treatment with injectable drugs in emergency medical settings, and currently are thought of to represent the agitation market. Alexza, however, believes the therapeutic market for agitation is broader than only this limited perspective of patients in severe crisis -- many more are in need of treatment for an agitation episode.

Alexza's primary market research indicates that approximately 50% of treated acute agitation episodes are treated in emergency settings. Another approximately 35% of the treated agitation episodes suffered by schizophrenic and bipolar patients are treated in an inpatient setting (hospital and long-term residential settings), and approximately 15% are treated in a physician's office.

Alexza's market research studies with schizophrenia patient caregivers and bipolar patients indicate these patients currently experience an average of 11 to 12 episodes of acute agitation each year.

Agitation episodes are currently treated about 55% of the time with oral antipsychotics and about 45% of the time with intra-muscular, or IM, injections. Oral medications work relatively slowly, but are easy to administer, painless and are less threatening to patients. IM injections have a faster onset of action and a higher predictability of drug effect, but because they are invasive and can be frightening to patients, IM injections are usually the treatment option of last-resort. Currently, no non-invasive therapies are available that work faster than 30 minutes to help agitated patients in need of treatment.

About AZ-004 (Staccato loxapine)

AZ-004 is an anti-agitation therapeutic that combines Alexza's proprietary
'/>"/>

SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Alexza Pharmaceuticals to Present at the 21st Annual Piper Jaffray Health Care Conference
2. Alexza to Announce 2009 Third Quarter Financial Results and Update Its AZ-004 NDA Status on Monday, November 9, 2009
3. Alexza Pharmaceuticals to Present at the Fourth Annual JMP Securities Healthcare Focus Conference
4. Alexza Announces Preliminary Results from its AZ-104 (Staccato(R) Loxapine) Phase 2b Trial in Patients with Migraine Headache
5. Alexza Reports 2009 First Quarter Financial Results and Updates Clinical Pipeline Status
6. Endo Pharmaceuticals and Alexza Pharmaceuticals Conclude Research Collaboration
7. Alexza Initiates AZ-104 (Staccato(R) Loxapine) Phase 2b Clinical Trial in Patients With Migraine Headaches
8. Alexzas AZ-004 (Staccato(R) Loxapine) Meets Primary Endpoint of Treating Acute Agitation in Patients with Bipolar Disorder in Phase 3 Trial
9. Alexzas AZ-004 (Staccato(R) Loxapine) Phase 3 Trial Meets Primary Endpoint of Treating Acute Agitation in Schizophrenic Patients
10. Alexza Reports 2008 Second Quarter Financial Results and Updates Development of Product Candidates
11. Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... WINNIPEG , March 27, 2015 /PRNewswire/ - Medicure ... Board of Directors has approved the grant of an ... management company employees and consultants of the Company pursuant ... 181,070 are set to expire on the tenth anniversary ... expire on the third anniversary of the date of ...
(Date:3/27/2015)... 27, 2015 /CNW Telbec/ - Russell Williams , ... Companies (Rx&D), welcomes the 2015-2016 Quebec Budget, noting the ... on the biopharmaceutical industry. However, the association is concerned ... "We commend the government,s intent to strive for a ... to promote Quebec,s economic development ...
(Date:3/27/2015)... 27, 2015 Biopharmaceutical Industry Leads Manufacturing ... comes out on top as the country,s manufacturing leader ... report  from ndp│analytics. According to the  analysis , the ... over the last decade, accounting for 27 percent of ... A Short Video on Medicare Part D ...
Breaking Medicine Technology:Quebec 2015-2016 Budget: Rx&D welcomes fiscal discipline and biopharma working group, but the decrease in government spending on medicines is questioned 2Quebec 2015-2016 Budget: Rx&D welcomes fiscal discipline and biopharma working group, but the decrease in government spending on medicines is questioned 3Week in Review: The Latest from PhRMA 2
(Date:3/28/2015)... Rocket Pure , a manufacturer of natural body ... new natural sunscreen. They are offering the sunscreen in ... come with a bonus lip balm sunscreen. , The new ... Click to see the natural sunscreen on Amazon . ... made with non-nano zinc oxide and provides broad-based protection against ...
(Date:3/28/2015)... With more than 4,500 scientists, clinicians ... osteoarthritis and musculoskeletal diseases gathered here for the ... first time in the 17-year history of the ... topic is an emerging non-pharmaceutical protocol for enhancing ... of Wolff’s law, osteogenic loading at multiples of ...
(Date:3/28/2015)... An article in Fortune on Monday, March ... to organizations that deal with PCI (Payment Card Information); ... security, is worsening . Using numbers from Verizon’s ... category out of the twelve measured improved, barring one ... craziness that has gone on in the retail industry ...
(Date:3/28/2015)... 28, 2015 Delaying rotator cuff surgery ... according to research presented today at the American Orthopaedic ... , “Our study compared results for 170 patients who ... additional glenohumeral joint capsule release procedure to relieve stiffness ... PhD, lead author from St. George Hospital in Sydney, ...
(Date:3/28/2015)... Aureus Medical Group (web: aureusmedical.com), a ... jobs, has announced that it will participate as ... Annual Conference to be held April 10-11, 2015 ... OH. , The OPTA Annual Conference offers ... and services. , Representatives from Aureus Medical’s ...
Breaking Medicine News(10 mins):Health News:Rocket Pure Releases New Natural Sunscreens For Athletes 2Health News:Rocket Pure Releases New Natural Sunscreens For Athletes 3Health News:Non-Drug Protocol for Building Bone Density Expected to Steal Spotlight at World Congress on Osteoporosis 2Health News:Businesses Dealing With PCI Falling Short On Regular Vulnerability Scans and Pen Testing 2Health News:Businesses Dealing With PCI Falling Short On Regular Vulnerability Scans and Pen Testing 3Health News:Businesses Dealing With PCI Falling Short On Regular Vulnerability Scans and Pen Testing 4Health News:No Need to Delay Rotator Cuff Surgery, Study Shows 2Health News:Healthcare Staffing Leader, Aureus Medical Group, to Exhibit at the Ohio Physical Therapy Association Annual Conference 2
... WASHINGTON , April 18 The Federal Court ... unanimous 3-judge decision,today issued an opinion supporting the ... holding that it is entitled to renew its,constitutional ... Columbia,s AccessRx Act of 2004., Last year, ...
... April 18 Breckenridge Pharmaceutical,Inc. announced today that ... approval for the Company,s Abbreviated New Drug Application ... Activella Tablets,(Estradiol/Norethindrone Acetate 1.0mg / 0.5mg) Tablets., ... a,brand product marketed by Novo Nordisk(R), which is ...
... result of age, body composition , , FRIDAY, April 18 ... younger age or body composition may not explain why ... of creatinine than white patients, says a U.S. study ... is a standard indicator of kidney function. A higher ...
... 18 Sales leaders and,organizations that regularly ... art of motivating their sales representatives. Organizations ... personnel can use the key findings,discovered in ... &,Recognizing Top-Performing Sales People.",( http://www3.best-in-class.com/dr295.htm ), ...
... ARBOR, Mich. Right now, about half of all people ... help from it. And doctors have no definitive way to ... prescription they write. , But a University of Michigan ... more certainty to how doctors and patients choose anxiety treatments, ...
... as much as drug treatments , , FRIDAY, April 18 ... symptoms in patients with terminal cancer, according to Japanese ... included a total of 517 patients with incurable cancer ... treatment for these patients was supportive expressive group therapy, ...
Cached Medicine News:Health News:PCMA: Court of Appeals Upholds Challenge to D.C.'s PBM Fiduciary-Disclosure Law 2Health News:Muscle Mass May Not Explain High Creatinine in Black Kidney Patients 2Health News:Complementary Excerpt Available from Best Practices: Rewarding and Recognizing Top-Performing Sales People 2Health News:High anxiety? 2Health News:High anxiety? 3Health News:High anxiety? 4Health News:Talk Therapy Proves Effective for Terminal Cancer Patients 2
IGF-BP3 EIA Endocrine Function 022-IGF-E03 Insulin Growth Factor binding protein...
... Angiotensin Converting Enzyme (ACE) is an integral ... the generation of Angiotensin II as well ... many different cell types, ACE is primarily ... only an important diagnostic parameter for sarcoidosis ...
Anti-Gliadin IgG (Ab) EIA Gastrointestinal Markers 027-GD16 Celiac Disease Food Allergy...
... evaluation of pancreatic -cell function is not only ... of the natural history of diabetes mellitus, but ... guide to the correct choice of treatment. Peripheral ... function because of the large and variable uptake ...
Medicine Products: